Editas Medicine Announces Second Quarter 2018 Results and Update
06 août 2018 16h05 HE
|
Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
06 août 2018 16h01 HE
|
Editas Medicine, Inc.
Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine’s experimental CRISPR genome editing...
Editas Medicine to Participate in The JMP Securities Life Sciences Conference
13 juin 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor...
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
08 mai 2018 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of...
Editas Medicine Announces First Quarter 2018 Results and Update
03 mai 2018 16h01 HE
|
Editas Medicine, Inc.
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield, Ph.D. Cash, cash equivalents, and...
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
30 avr. 2018 13h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from...
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
26 avr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
28 mars 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the...
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
06 mars 2018 16h01 HE
|
Editas Medicine, Inc.
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22...
Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
28 févr. 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and...